Literature DB >> 26603684

Prognosis of gastric adenocarcinoma patients with various burdens of peritoneal metastases.

Hironori Shiozaki1, Elena Elimova1, Rebecca S Slack2, Hsiang-Chun Chen2, Gregg A Staerkel3, Nour Sneige3, Yusuke Shimodaira1, Tara Sagebiel4, Jeffrey H Lee5, Manoop S Bhutani5, Prajnan Das6, Paul F Mansfield7, Jeannelyn S Estrella3, Brian D Badgwell7, Jaffer A Ajani1.   

Abstract

BACKGROUND: Peritoneal metastases (PM) in patients with gastric adenocarcinoma (GAC) may be identified by diagnostic laparoscopy (DL) or imaging (I). Although prognosis is poor, some patients have excellent outcome. We compared the overall survival (OS) of patients in 3 groups: those with positive cytology (CY+) by DL (DL-CY+), those with gross PM (GPM) by DL (DL-GPM+) and with GPM obvious on I (I-GPM+).
METHODS: 146 GAC patients were identified. The Kaplan-Meier analysis, univariate, and multivariate Cox proportional hazards regression models were employed.
RESULTS: Patients were primarily men (67%), with good ECOG scores (0-1; 89%), had DL (84%), had poorly differentiated GAC (92%), and had received chemotherapy (89%). The median OS for all patients was 15 months (5% CI, 12.9-18.2 months). The DL-CY+ group had median OS of 22.5 months (95% CI, 15-29.3 months). Patients with I-GPM+ had four times the risk of death than those with DL-CY+ (P < 0.001) and patients with DL-GPM+ had two times the risk of death than those with DL-CY+ (P = 0.001). At 36 months, all DL-GPM+ and I-GPM+ had died but 8 patients with DL-CY+ remained alive.
CONCLUSIONS: Some GAC patients with DL-CY+ have long OS; therefore, novel strategies to further prolong their OS are needed.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  cytology; gastric adenocarcinoma; outcome; peritoneal metastases

Mesh:

Year:  2015        PMID: 26603684     DOI: 10.1002/jso.24087

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  12 in total

1.  Risk of peritoneal metastases in patients who had negative peritoneal staging and received therapy for localized gastric adenocarcinoma.

Authors:  Dilsa Mizrak Kaya; Graciela M Nogueras-González; Kazuto Harada; Fatemeh G Amlashi; Sinchita Roy-Chowdhuri; Jeannelyn S Estrella; Prajnan Das; Jeffrey H Lee; Brian Weston; Manoop S Bhutani; Aurelio Matamoros; Irene Thomas; Quan Lin; Brian D Badgwell; Jaffer A Ajani
Journal:  J Surg Oncol       Date:  2017-12-04       Impact factor: 3.454

2.  Next-Generation Sequencing Analysis of Gastric Cancer Identifies the Leukemia Inhibitory Factor Receptor as a Driving Factor in Gastric Cancer Progression and as a Predictor of Poor Prognosis.

Authors:  Cristina Di Giorgio; Silvia Marchianò; Elisabetta Marino; Michele Biagioli; Rosalinda Roselli; Martina Bordoni; Rachele Bellini; Ginevra Urbani; Angela Zampella; Eleonora Distrutti; Annibale Donini; Luigina Graziosi; Stefano Fiorucci
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

3.  5-Year Survival in Gastric Adenocarcinoma with Epithelial and Stromal Versican Expression.

Authors:  Mohammad Hossein Sanei; Omid Mirmosayyeb; Ali Chehrei; Jamshid Ansari; Elahe Saberi
Journal:  Iran J Pathol       Date:  2018-12-27

4.  Intraperitoneal cancer-immune microenvironment promotes peritoneal dissemination of gastric cancer.

Authors:  Shuichi Sakamoto; Shunsuke Kagawa; Kazuya Kuwada; Atene Ito; Hiroki Kajioka; Yoshihiko Kakiuchi; Megumi Watanabe; Tetsuya Kagawa; Ryuichi Yoshida; Satoru Kikuchi; Shinji Kuroda; Hiroshi Tazawa; Toshiyoshi Fujiwara
Journal:  Oncoimmunology       Date:  2019-10-22       Impact factor: 8.110

Review 5.  Cytoreductive Surgery for Peritoneal Carcinomatosis from Gastric Cancer: Technical Details.

Authors:  Thomas Boerner; Pompiliu Piso
Journal:  J Clin Med       Date:  2021-11-12       Impact factor: 4.241

6.  Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma.

Authors:  Ruiping Wang; Minghao Dang; Kazuto Harada; Guangchun Han; Fang Wang; Melissa Pool Pizzi; Meina Zhao; Ghia Tatlonghari; Shaojun Zhang; Dapeng Hao; Yang Lu; Shuangtao Zhao; Brian D Badgwell; Mariela Blum Murphy; Namita Shanbhag; Jeannelyn S Estrella; Sinchita Roy-Chowdhuri; Ahmed Adel Fouad Abdelhakeem; Yuanxin Wang; Guang Peng; Samir Hanash; George A Calin; Xingzhi Song; Yanshuo Chu; Jianhua Zhang; Mingyao Li; Ken Chen; Alexander J Lazar; Andrew Futreal; Shumei Song; Jaffer A Ajani; Linghua Wang
Journal:  Nat Med       Date:  2021-01-04       Impact factor: 53.440

7.  Dual-Energy Computed Tomography-Based Radiomics to Predict Peritoneal Metastasis in Gastric Cancer.

Authors:  Yong Chen; Wenqi Xi; Weiwu Yao; Lingyun Wang; Zhihan Xu; Michael Wels; Fei Yuan; Chao Yan; Huan Zhang
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

8.  Hyperthermic intraperitoneal chemotherapy combined with systemic chemotherapy for gastric cancer peritoneal carcinomatosis: A protocol for systematic review and meta-analysis of randomized controlled trials.

Authors:  Yidan Lu; Zheng Jin; Song Zheng; Yurong Bai; Yangcheng Sun
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

9.  Optimizing outcomes for patients with gastric cancer peritoneal carcinomatosis.

Authors:  Jennifer L Leiting; Travis E Grotz
Journal:  World J Gastrointest Oncol       Date:  2018-10-15

10.  Staging laparoscopy and peritoneal cytology in patients with early stage gastric adenocarcinoma.

Authors:  Casey J Allen; Alisa N Blumenthaler; Prajnan Das; Bruce D Minsky; Mariela Blum; Sinchita Roy-Chowdhuri; Jaffer A Ajani; Naruhiko Ikoma; Paul F Mansfield; Brian D Badgwell
Journal:  World J Surg Oncol       Date:  2020-02-17       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.